HighTower Advisors
CUE icon

HighTower Advisors’s Cue Biopharma CUE Stock Holding History

HighTower Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-364
Closed -$3.34K – 3832
2025
Q4 		$3.34K Buy
+364
New +$6.69K ﹤0.01% 3643
2025
Q2 		– Sell
-4,276
Closed -$117K – 3798
2025
Q1 		$117K Hold
4,276
– – ﹤0.01% 3332
2024
Q4 		$140K Buy
4,276
+1,500
+54% +$56.4K ﹤0.01% 3297
2024
Q3 		$64K Hold
2,776
– – ﹤0.01% 3380
2024
Q2 		$103K Buy
2,776
+193
+7% +$9.54K ﹤0.01% 3200
2024
Q1 		$147K Sell
2,583
-21
-0.8% -$1.48K ﹤0.01% 3063
2023
Q4 		$206K Hold
2,604
– – ﹤0.01% 2986
2023
Q3 		$181K Buy
2,604
+67
+3% +$6.54K ﹤0.01% 2944
2023
Q2 		$278K Hold
2,537
– – ﹤0.01% 2614
2023
Q1 		$272K Buy
+2,537
New +$242K ﹤0.01% 2532

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

HighTower Advisors's CUE Position: Q1 2026 in Review

HighTower Advisors sold out of Cue Biopharma (CUE) in Q1 2026, closing a stake of 364 shares — an estimated $3.34K sold.

HighTower Advisors first reported a position in CUE in Q1 2023 and held it in 10 quarters. The position peaked at $278K in Q2 2023. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • HighTower Advisors reported no remaining Cue Biopharma position as of Q1 2026 after selling out during the quarter.
  • HighTower Advisors sold 364 Cue Biopharma shares in Q1 2026, an estimated $3.34K.
  • HighTower Advisors first reported a position in Cue Biopharma in Q1 2023 and held it in 10 quarters.
  • HighTower Advisors's Cue Biopharma position peaked at $278K in Q2 2023.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.